Furthermore, AML stem cell assays are complex and time-consuming and not suitable for routine practice, whereas estimation of the CD34+CD38− AML cell burden is not a time-consuming analysis and the results can therefore be included in the initial/pre-chemotherapy patient evaluation. This evidence concerns the gene CD38 and acute myeloid leukemia.